Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Almirall, a global pharmaceutical company, has announced the efficacy of Sativex (2.7 mg delta-9-tetrahydrocannabinol and 2.5 mg cannabidiol per puff) from three Phase III studies, to treat spasticity in Multiple Sclerosis (MS).
Subscribe to our email newsletter
Sativex has been developed by the UK-based GW Pharmaceuticals and is marketed in Europe (except the UK) by Almirall.
The Phase III studies demonstrated the long term efficacy of Sativex (2.7 mg delta-9-tetrahydrocannabinol and 2.5 mg cannabidiol per puff) in patients with moderate to severe spasticity due to multiple sclerosis.
Almirall Chief Scientific Officer Bertil Lindmark said the positive results provide an opportunity to help patients with MS spasticity.